Evaluation of Insulin and Glucagon-like peptide-1 Receptor Agonists Combination for Type 2 Diabetes Mellitus: An Updated Meta-analysis

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RA) increase glucose-stimulated insulin secretion, suppress glucagon production, increase satiety, reduce food intake, improve insulin sensitivity, and reduce visceral fat. This study aims to compare the GLP-1RA and insulin combination or GLP-1RA added to background insulin therapy with other injectable therapies in patients with type-2 diabetes mellitus (T2DM). We searched for studies that compared GLP-1RA and insulin combination with other injectable therapies in T2DM patients for HbA1c (%) change, achieving HbA1c <7% at study end, hypoglycemia incidence, and weight change. The following intervention groups were analyzed: the combination of basal insulin and GLP-1RA, basal-plus/basal-bolus, and placebo/insulin intensification (insulin uptitration)/GLP-1RA. A total of 48 studies were included. Insulin and GLP-1RA combination therapy reduced HbA1c more than placebo/insulin intensification (insulin up-titration)/GLP-1RA (WMD -0.693, p <0.001) and basal-plus/basal-bolus (WMD -0.105, p ≤0.027). Insulin and GLP-1RA combination therapy significantly reduced body weight more than placebo/insulin intensification (insulin up-titration)/GLP-1RA (WMD -1.894, p <0.001) and basal-plus/basal-bolus (WMD -3.6, p ≤0.001). Patients on insulin and GLP-1RA combination therapy had a higher chance of achieving the HbA1c target than placebo/insulin intensification (insulin up-titration)/GLP-1RA arm (RR 1.964, p <0.001), but not than basal-plus/basal-bolus arm (RR 1.037, 95% CI 0.971 to 1.103). Hypoglycemia rates were comparable between combination therapy and placebo/insulin intensification (insulin up-titration)/GLP-1RA (RR 0.94, 95% 0.84 - 1.04), but statistically significant when compared to combination therapy and basal-plus/basal-bolus (RR 0.63, p <0.001). Our findings support using GLP-1RA in combination with insulin as a useful intensification approach for producing therapeutic improvement in T2DM therapy for individuals who have not reached their HbA1c goal.

References

1. 1.Ebada MA, Fayed N, Fayed L, Alkanj S, Abdelkarim A, Farwati H, et al. Efficacy of alpha-lipoic acid in the management of diabetes mellitus: A systematic review and meta-analysis. Iran J Pharm Res. 2019;18(4):2144–56.
2. 2.Abdelhaleem IA, Salamah HM, Alsabbagh FA, Eid AM, Hussien HM, Mohamed NI, et al. Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus:Asystematic review and meta-analysis of randomized clinical trials. Diabetes Metab Syndr Clin Res Rev. 2021;15(6):102323.
3. 3.Webber S. International Diabetes Federation. Vol. 102, Diabetes Research and Clinical Practice. 2013. p. 147–8.
4. 4.Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of PatientsandPhysiciansinInsulinTherapy study. Diabet Med. 2012;29(5):682–9.
5. 5.Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006-2013. In: Diabetes Care. 2017. p. 468–75.
6. 6.Montvida O, Shaw J, Atherton JJ, Stringer F, Paul SK. Long-term trends in antidiabetes drug usage in the U.S.: Real-world evidence in patients newly diagnosed with type 2 diabetes. Diabetes Care. 2018;41(1):69–78.
7. 7.Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K. Efficacy of insulin analogs in achieving the hemoglobinA1c target of <7% in type 2 diabetes: Meta-analysis of randomized controlled trials. Diabetes Care. 2011;34(2):510–7.